CN1695678A - Medication for anti ischemia on heart and brain, as well as preventing and treating fatty liver - Google Patents
Medication for anti ischemia on heart and brain, as well as preventing and treating fatty liver Download PDFInfo
- Publication number
- CN1695678A CN1695678A CN 200510010790 CN200510010790A CN1695678A CN 1695678 A CN1695678 A CN 1695678A CN 200510010790 CN200510010790 CN 200510010790 CN 200510010790 A CN200510010790 A CN 200510010790A CN 1695678 A CN1695678 A CN 1695678A
- Authority
- CN
- China
- Prior art keywords
- ischemia
- blood
- myocardial
- cardiac
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A Chinese medicine for preventing and treating cardiac and cerebral ischemia and fatty liver is prepared from arasaponin extracted from notoginseng, the ginkgolide and ginkgetin extracted from ginkgo leaf, and the polydanshinolic acid and danshinon extracted from red sage root.
Description
Technical field
The present invention relates to field of pharmaceutical technology, specifically a kind of anti-cardiac-cerebral ischemia, lipotropic medicine.
Background technology
Based on the cardiovascular and cerebrovascular disease of cardiac-cerebral ischemia, can develop into critical illnesses such as heart infarction, cerebral infarction, be common complaint among the elderly and frequently-occurring disease, now approached 42～60 years old middle age, prevalence rises with age.The cause of disease of its formation is hyperlipidemia, hypertension, high blood viscosity and heart and brain atherosclerosis and diabetes.During hypertension incidence, since the tiny arteriospasm of whole body, the tube wall anoxia, tiny arterial endothelial cell hardening, tube wall thickens, hardening, and tube chamber dwindles, and symptoms such as headache, dizziness, dim eyesight may appear in patient.Endovascular deposit is many during morbidity, and the Peripheral resistance of blood flow increases, and just makes hypertension.When the diastolic pressure back heart that raises holds and can't stand, just make that left ventricle thickens, hypertrophy, cardiac muscle is in relative ischemic state, can produce uncomfortable in chest, cardiopalmus, has palpitation, arrhythmia, and somebody's palmic rate is accelerated to remedy deficiency myocardial blood supply; The old man causes heart failure easily because ventricular systole power reduces.Hyperpietic's whole blood viscosity generally is higher than normal healthy people.Erythrocyte in hyperlipidemia, the high blood viscosity patient blood gathers, and red cell deformability is poor, rigidity is big, is difficult to pour into blood capillary, causes the bad and myocardial ischemia-anoxemia of microcirculation.The people causes the damage of ductus arteriosus wall and permeability to increase when hypertension easily, impels lipoprotein to be deposited in the ductus arteriosus wall, and atherosclerosis is increased the weight of.When arterial lumen was narrow, atrophy can take place in the long-term blood supply insufficiency of cerebral tissue, symptoms such as patient often has a headache, dizziness, feeling of fullness in the head, insomnia, hypomnesis.Diastolic pressure increases the risk factor for cerebral hemorrhage.Behind the coronary artery luminal stenosis of cardiac muscle, symptoms such as pained, uncomfortable in chest, premature beat can take place in myocardial ischemia; When stenosis reached 70～75%, angina pectoris can take place.But many coronary disease patients are not in the mood for pain at ordinary times, can suffer from myocardial infarction suddenly yet.Current to coronary disease patient employing " Coronary Artery Bypass " or " intervention " stenting, though can save critical patient's life, undesirable.After performing an operation, ten thousand yuan to tens0000 yuan of many people Hua Liaowu still have sensation pained, uncomfortable in chest, its reason is that the doctor can not perform an operation to the tiny tremulous pulse of arteria coronaria, fail to solve tiny arterial wall thickness, luminal stenosis, blood flow is little and myocardium microcirculation problem, also fail to solve the microcirculation problem of three big arteria coronaria itself, so also have pained sense, cardiac muscle still is in ischemic state.The doctor can only lean on the open medicine with blood vessel dilating, improves blood supply of cardiac muscle and microcirculation.The expense of operation and medicine gives patient with heavy financial burden.Some patient behind the operation on heart seals breast often, and is pained unable, has difficulty in walking quality of life and poor life quality.Medical expert and patient think to find an ideal solution.
Summary of the invention
The purpose of this invention is to provide a kind for the treatment of both the principal and secondary aspects of a disease, can reach the anti-cardiac-cerebral ischemia that improves body function, lipotropic medicine.
Medicine of the present invention is by Radix Notoginseng total arasaponins, Folium Ginkgo extract, and three kinds of medicines of poly phenolic acid of Radix Salviae Miltiorrhizae (or tanshinone) are formed, and its percentage by weight is as follows:
Radix Notoginseng total arasaponins 15～60%,
Folium Ginkgo extract 15～70%,
Radix Salviae Miltiorrhizae extract 0.5～40%.
Wherein: Radix Notoginseng total arasaponins contains ginsenoside Rb1, ginsenoside Rg1; Apricot yellow ketone of Folium Ginkgo extract argentiferous and Semen Ginkgo lactone, Radix Salviae Miltiorrhizae extract are poly phenolic acid of Radix Salviae Miltiorrhizae or tanshinone.
Of the present invention studies show that:
1, Radix Notoginseng is rich in a large amount of R
B1R with middle amount
G1, R
B1And R
G1Can stimulate the metabolism of user's blood fat and cholesterol, and can promote the RNA in the nucleus to produce nascent protein, increase resistant function.Studies confirm that through many-sided Radix Notoginseng total arasaponins has resisting fatigue, anoxia enduring, many-sided strengthening by means of tonics effect such as blood viscosity lowering.And can take safety non-toxic for a long time.
2, Folium Ginkgo extract can be removed free radical rapidly, prevents that effectively high-fat cell membrane is oxidized, or after the free radical pair cell destroys, recovers the complete of cell membrane again.It can recover some acceptance points miraculously in brain cell, increase the transmission of 5-hydroxy tryptamine (a kind of important brain chemical substance), to reverse and to delay the brain aging that fades away and cause, prevent senile dementia owing to this material (5-hydroxy tryptamine).
3, Radix Salviae Miltiorrhizae extract has remarkable coronary blood flow increasing, improves the myocardial metabolism disorder that causes after the anoxia, thereby improves myocardial hypoxia tolerance.The effect that has the protection erythrocyte membrane simultaneously.And can dwindle the laboratory animal myocardial infarction area.Under doses, still can strengthen myocardial contraction.Studies have shown that to have calcium channel blocking action, reduce myocardial excitability and conductivity recently, the myocardial damage due to the acute myocardial ischemia anoxia is had obvious protective effect.Radix Salviae Miltiorrhizae extract also has the blood microcirculation of improvement, antiplatelet gathering and thrombosis, and blood viscosity is descended, and these effects help improving blood circulation, and are useful to the protection of myocardial ischemic injury.To the protective effect of cerebral tissue ischemia/reperfusion injury, strengthen hypoxia-bearing capability, renal blood flow (RBF) is significantly increased, renal function obviously improves.Can also significantly increase the discharge of carbamide in the urine, creatinine, sodium and Phos.Improve the effect of ability of learning and memory.
The above-mentioned compatibility of drugs of the present invention, its effect is complemented each other, and effect is better.Be mainly used in anti-cardiac-cerebral ischemia, the control fatty liver.It can coronary artery dilator, coronary blood flow increasing, and decreased heart rate increases myocardial contraction, improves the myocardial metabolism disorder and the cardiac function that cause after the anoxia.Full side cooperates, and complementation is short mutually, Synergistic, and effect is remarkable, and treating both the principal and secondary aspects of a disease, can reach the purpose of improving body function.
The present invention compared with prior art, its outstanding substantive distinguishing features and obvious improvement is:
1. taking dose is little, each 0.3g, every day 2 times.The present invention is under Chinese medical theory instructs, preferred above-mentioned Chinese crude drug extract, and in addition scientific and reasonable compatibility cooperatively interacts each medicine, and Synergistic is obvious, and effect is remarkable.
2. through clinical verification, the present invention can prevent myocardial infarction, improves blood microcirculation, and is useful to the protection of myocardial ischemic injury, and the cerebral tissue ischemia/reperfusion injury is shielded.
3. from the angle analysis of modern medicine, the present invention has the ischemia of alleviating, anoxia body injury, suppresses thrombosis, improves blood circulation, increases the function of blood flow and oxygen-supplying amount.It is by blood vessel dilating and stop undue thickness of blood and platelet deposition to stimulate blood circulation, tissue is increased oxygen supply, help blood more to waltz through the most tiny and narrow blood vessel, make the anoxia in brain, heart and the extremity tissue partly obtain nutrition, thereby play the effect that regains the strength of memory and eliminate myalgia.
4. the acute toxicity of product of the present invention and chronicity toxicity research result show, take product of the present invention for a long time, are efficient, safe.
5. medicine taking dose of the present invention is little, easily absorbs metabolism, and produce effects is fast, curative effect is high.
6. the present invention is raw materials used is easy to get, the prescription science, and production technology is easy, and is workable, is fit to the health industrial policy of China's prevention cardiovascular and cerebrovascular disease, and the moderate product price of producing is fit to suitability for industrialized production, and can make the numerous common people be easy to accept.
7. according to the active ingredient character and the preparation requirement of each flavor Chinese medicine, adopt the extraction process, sterilizing methods, the production technology that adapt in producing, thus make product effective component content height, and not perishable, thus make the shelf-life longer.
Below be the efficacy experiment of medicine of the present invention:
One, material
1. medicine and reagent
Medicine of the present invention (ischemia resisting capsule), every contains brownish red powder 0.35g, and recommending clinical people's consumption is 1/time, divides early, day in evening obeys twice, and laboratory sample adopts and is unkitted capsular raw material.Commercially available Herba Erigerontis tablet, the 20mg/ sheet, lot number 20040616 is produced by Pharmaceutical Factory, Medicine Inst., Yunnan Prov..Nimodipine (Ni Daer sheet), the 20mg/ sheet, the Tianjin Central Pharmaceutical Co., Ltd produces, lot number 020801.Above sample all is mixed with the suspension of desired concn for rat oral gavage usefulness with 0.5%CMC-Na.Red tetrazolium (TTC), import, the AMRESCO packing, lot number 0765, Shanghai is given birth to the worker and is produced.Adenosine diphosphate sodium (ADP), lot number A2754, Sigma company produces, the import packing, produce in Beijing ancient cooking vessel state biotech development center.AST (ultraviolet KINETIC METHOD, lot number 0704151), LDH (ultraviolet KINETIC METHOD, (selectivity suppresses KINETIC METHOD for lot number 0704102, CK-MB, lot number 100412), TT (lot number 0504052), PT (lot number 0604161), APTT (lot number 0604131) and FIB (lot number 060405) measure test kit, be Sichuan Mai Ke Science and Technology Ltd. and produce.
2. animal
A cleaning level SD rat, male, body weight 240～385g, the quality certification number: SCXK (Shanghai) 2003-0002, derive from west, Shanghai pul-must triumphant laboratory animal company limited, buy on behalf by unming Medical College's Experimental Animal Center.
3. instrument
The TM1024 automatic clinical chemistry analyzer, Tokyo Co., Ltd.; Centrifuge 5810R type refrigerated centrifuger, German eppendoff company; BS110 type electronic analytical balance, Sai Duolisi company; Millipore ultra-pure water processing system, U.S. Millipore company; 6951D type electrocardiograph, Shanghai photoelectricity company; C2000-4 coagulo meter and LBY-NS platelet aggregation instrument, Beijing Puli gives birth to group.
4. add up
The result represents that with X ± SD the normal distribution data are checked with t, the rank test of skewness distributed data.
Two, method
1. rat coronary artery ligation myocardial ischemia experiment
1.1 experiment grouping and moulding:
Male SD rat, 330～385g is divided at random by body weight: blank group, model group, Herba Erigerontis tablet 40mg/kg group, ischemia resisting capsule 140,420mg/kg group.Each treated animal according to dosage every day gastric infusion once, continuous 5 is big, blank group and model group wait capacity 0.5%CMC-Na 10ml/kg body weight.30min after the last administration, with 12% chloral hydrate lumbar injection 350mg/kg anesthetized animal, the row open chest surgery exposes heart, finds out left anterior descending coronary artery between pulmonary conus and left atrium, and apart from root 2～3mm place's ligation, heart resets and closes the thoracic cavity fast.Sham operated rats is only put the end of a thread and not ligation.
1.2 detection index:
Write down before the ligation respectively and ligation after 5 minutes, 30 minutes, 1h, 2h, 4h and 24h limbs II lead electrocardiogram, measure S-T section (J point) changing value.Behind the 24h electrocardiogram to be recorded, the carotid artery intubate is got two parts of blood: a separation of serum is pressed the activity that kit method is measured AST, LDH and CK-MB; With anticoagulant in 1: 9, the centrifugal 5min of 1000rpm prepared platelet rich plasma (PRP) to portion with 3.8% sodium citrate, and the centrifugal 10min of 3500rpm prepares platelet poor plasma (PPP).By the inductive platelet aggregation rate of turbidimetry for Determination ADP-2Na, the final concentration of ADP is 6mol/L; Measure TT, PT, APTT and FIB respectively by kit method.Extract heart rapidly after getting blood, place the ice normal saline to pump hematocele in the chambers of the heart, remove atrium and fatty tissue, suck dry moisture takes by weighing ventricle and weighs, and is cut into 5 with tailing edge is crown, and lucifuge is hatched dyeing 10min in 37 ℃ in 1%TTC solution.After dyed, the normal myocardium tissue takes on a red color, and infarction tissue is white in color, and blocking part is cut weighed, and it is myocardial infarct size that the downright bad part of calculating accounts for the heavy percentage ratio of ventricle.
2. rat MCAO focal cerebral ischemia experiment
2.1 experiment grouping and moulding:
Male SD rat, body weight 240～290g, grouping and dosage are the same, and other establishes positive control drug nimodipine 50mg/kg group.Each treated animal every day according to dosage gastric infusion once, continuous 5 days.30min behind the last filling stomach, with 12% chloral hydrate lumbar injection 350mg/kg anesthetized animal, left lateral position, cut skin along auris dextra informer mid point, separate temporalis, the disconnected cheekbone of strand is holed with dental burr in cheekbone root the place ahead, exposes MCA, between inferior cerebral vein and tractus olfactorius, provoke with pin, break it, after the cotton balls hemostasis by compression, layering suture muscles and skin.Sham operated rats is not except choosing disconnected MCA, and all the other steps are identical.
2.2 observation index:
Animal 6h and 24h after modeling carry out function of nervous system's scoring according to behaviors such as motion performance, with this as the disordered brain function index.Blind method is adopted in scoring, and promptly scoring person does not know the situation of administration, and standards of grading are as follows:
| Symptom | The behavior disorder scoring |
| Carry the about chi of Mus tail built on stilts, the wrist flexing appears in operation offside forelimb, and the elbow flexing is takeed on inward turning or wrist is arranged, and the elbow flexing has inward turning again.Animal is placed on the plane earth, push away both shoulders respectively to the inside, check resistance.Animal is placed on the metal wire side, observe the tension force of two forelimbs.Animal is placed on the plane earth, observe to have or not and turn-take.Full marks | 1～4 1～3 1～3 1～2 12 |
Above standard full marks are 12 minutes, and mark is high more, show that the animal behavior obstacle is serious more
Modeling 24h, after function of nervous system's scoring, the carotid artery intubate is got blood, and a separation of serum is pressed the activity that kit method is measured AST and LDH; With anticoagulant in 1: 9, the centrifugal 5min of 1000rpm prepared platelet rich plasma (PRP) to portion with 3.8% sodium citrate, and the centrifugal 10min of 3500rpm prepares platelet poor plasma (PPP).By the inductive platelet aggregation rate of turbidimetry for Determination ADP-2Na, the final concentration of ADP is 6mol/L; Measure TT, PT, APTT and FIB respectively by kit method.Quick broken end is got brain after getting blood, puts into the ice normal saline and removes olfactory bulb, cerebellum and low brain stem, and suck dry moisture takes by weighing brain and weighs, and is cut into 5 along crown, inserts 5ml and contains 4%TTC and 1mol/LK
2HPO
40.1ml solution in, lucifuge is incubated 30min in 37 ℃ of temperature, stir once every 7-8min therebetween, after dyed, normal cerebral tissue is rose, and infarction tissue is white in color, and blocking part is cut weighed, and calculates infarction tissue's weight with the weight area method and accounts for the heavy percentage ratio of bilateral cerebral hemisphere as the cerebral infarction scope.
Three, result
1. to the influence of rat coronary artery ligation myocardial ischemia
1.1 influence to myocardial ischemia electrocardiogram S-T section:
Behind the model group rat ligation coronary artery, S-T section on the electrocardiogram (J point) obviously raises or descends, and sham operated rats then changes not quite, shows experiment modeling success.The ischemia resisting capsule can obviously reduce the variation of each time point S-T section, the electrocardiogram effect of having clear improvement when showing myocardial ischemia.The results are shown in Table 1.
Table 1. ischemia resisting capsule is to the influence of rats with myocardial ischemia electrocardiogram S-T section
| Group sham-operation model Herba Erigerontis tablet ischemia resisting | Dosage (/kg) 10ml 10ml 40mg 40mg 420mg | Number of animals (only) 10 11 12 9 11 | ST section variation after the ligation (X ± SD, mv) | |||||
| ??5min ??0.06±0.06 ??0.37±0.12 △△????0.15±0.14 **??0.12±0.06 **??0.10±0.06 ** | ??30min ??0.05±0.05 ??0.24±0.09 △△????0.09±0.08 **??0.11±0.08 **??0.06±0.05 ** | ??1h ??0.04±0.05 ??0.14±0.08 △△????0.07±0.06 *??0.08±0.06 ??0.06±0.04 ** | ??2h ??0.06±0.04 ??0.16±0.08 △△????0.07±0.07 **??0.07±0.07 *??0.07±0.05 * | ??4h ??0.06±0.05 ??0.16±0.10 △△????0.08±0.06 *??0.11±0.07 ??0.08±0.06 * | 24h 0.01±0.02 0.18±0.14 △△0.02±0.03 **0.05±0.06 *0.02±0.03 ** | |||
Compare with sham operated rats: △ P＜0.01; Compare with model group: * P＜0.05, * * P＜0.01;
1.2 influence to rats with myocardial ischemia cardiac muscle zymetology:
Model group rat blood serum AST, LDH and CK-MB activity have increasing in various degree, increase more obviously especially with CK-MB and LDH activity, show myocardial damage modeling success.Ischemia resisting capsule two dosage groups can obviously reduce the release of CK-MB and LDH, and have the trend that reduces AST, show that to alleviate the myocardial cell injury effect remarkable; The myocardial infarct size of two administration group rats is all significantly less than model control group, compares with model group and dwindles 49.69% and 61.80% respectively.The results are shown in Table 2.
Table 2. ischemia resisting capsule is to the influence of rats with myocardial ischemia myocardial infarct size and zymetology
| Group | Dosage (/kg) | Number of animals (only) | The cardiac muscle zymetology (X ± SD, ku/L) | Myocardial infarct size | |||
| ??AST | ??LDH | ??CK-MB | ??(X±SD，％) | Minification | |||
| Sham-operation model Herba Erigerontis tablet ischemia resisting | ??10ml ??10ml ??40mg ??140mg ??420mg | ??10 ??11 ??12 ??9 ??11 | ??0.52±0.21 ??0.72±0.35 ??0.68±0.33 ??0.62±0.28 ??0.52±0.13 | ??0.82±0.21 ??1.08±0.27 △????0.94±0.42 ??0.74±0.29 *??0.57±0.28 ** | ??0.65±0.26 ??2.06±1.30 △△????0.92±0.64 *??1.12±0.81 *??0.74±0.84 * | ??0.19±0.27 ??6.44±3.62 △△????3.09±1.58 *??3.24±2.13 *??2.46±1.41 ** | ??- ??- ??52.02 ??49.69 ??61.80 |
Compare with sham operated rats: △ P＜0.01; Compare with model group: * P＜0.05, * * P＜0.01;
1.3 coronary artery ligation is caused the influence of rats with myocardial ischemia platelet aggregation and blood coagulation:
After the rat coronary artery ligation caused the myocardial ischemia modeling, platelet aggregation rate obviously raise, and there is shortening trend the ATPP time, and fibrinogenic content obviously increases.The ischemia resisting capsule can obviously suppress the inductive platelet aggregation by ADP, and the fibrinogen content of reduction is arranged and prolong TT, the trend of APTT time.The results are shown in Table 3.
Table 3. ischemia resisting capsule is to the influence of rats with myocardial ischemia blood clotting and platelet aggregation
| Group | Dosage (/kg) | Number of animals (only) | The blood clotting index | Platelet aggregation rate (%) | |||
| ??TT ??(s) | ??PT ??(s) | ??APTT ??(s) | ??FIB ??(g/L) | ||||
| Sham-operation model Herba Erigerontis tablet ischemia resisting | ??10ml ??10ml ??40mg ??140mg ??420mg | ??10 ??11 ??12 ??9 ??11 | ??77.14±25.12 ??72.37±40.79 ??92.49±34.44 ??79.90±41.99 ??82.93±23.95 | ??23.74±6.65 ??24.56±4.96 ??26.58±3.81 ??26.65±4.66 ??25.54±4.08 | ??85.95±30.16 ??56.58±41.58 ??69.74±33.82 ??63.01±39.07 ??79.87±25.40 | ??3.57±0.49 ??4.75±1.19 △△????3.90±0.96 ??3.56±1.05 ??4.44±1.26 | ??49.00±6.34 ??57.50±4.00 △△????48.93±7.22 **??47.88±10.47 *??45.94±12.65 * |
Compare with sham operated rats: △ P＜0.05, △ △ P＜0.01; Compare with model group: * P＜0.05, * * P＜0.01;
2. MCAO is caused the influence of focal cerebral ischemia rat
2.1 influence to MCAO rat delayed ischemic neurological deficits and cerebral infarction scope:
After the rat MCAO modeling, the dyskinesia in various degree appears in movable the minimizing, and model group is compared significant difference with sham operated rats.The ischemia resisting capsule can obviously improve the delayed ischemic neurological deficits of MCAO rat, the scope of dwindling cerebral infarction, and two dosage groups dwindle 40.91% and 54.07% respectively.The results are shown in Table 4.
Table 4. ischemia resisting capsule is to the influence of MCAO rat delayed ischemic neurological deficits and cerebral infarction scope
| Group | Dosage (/kg) | Number of animals (only) | The cerebral infarction scope | Behavioristics's scoring (X ± SD divides) | ||
| ??(X±SD，％) | Minification | ??6h | ??24h | |||
| Sham-operation model nimodipine Herba Erigerontis tablet ischemia resisting | ??10ml ??10ml ??50mg ??40mg ??140mg ??420mg | ??10 ??11 ??12 ??11 ??10 ??11 | ??0.04±0.09 ??5.77±2.59 △△????3.08±2.22 **??3.74±2.36 **??3.41±2.59 *??2.65±1.58 ** | ??- ??- ??57.58 ??48.48 ??40.91 ??54.07 | ??0.6±0.97 ??8.73±1.01 △△????6.17±0.83 **??6.58±1.08 **??7.20±1.23 **??6.27±1.10 ** | ??0.60±1.08 ??7.54±1.29 △△????5.50±1.09 **??5.83±1.03 **??6.00±1.41 *??5.18±1.40 ** |
Compare with sham operated rats: △ P＜0.01; Compare with model group: * P＜0.05, * * P＜0.01;
2.2 influence to inductive MCAO rat platelet aggregation of ADP and blood coagulation:
After the rat MCAO modeling, platelet aggregation rate obviously increases, and clotting time shortens to some extent and fibrinogenic content has the trend of increase.The ischemia resisting capsule can obviously suppress the inductive platelet aggregation by ADP, and has the fibrinogen content of reduction and prolong TT, the trend of APTT time.The results are shown in Table 5.
Table 5. ischemia resisting capsule and ischemia resisting capsule are to the influence of MCAO rat blood clotting and platelet aggregation (X ± SD)
| Group | Dosage (/kg) | Number of animals (only) | The blood clotting index | Platelet aggregation rate (%) | |||
| ??TT ??(s) | ??PT ??(s) | ??APTT ??(s) | ??FIB ??(g/L) | ||||
| Sham-operation model nimodipine Herba Erigerontis tablet ischemia resisting | ??10ml ??10ml ??50mg ??40mg ??140mg ??420mg | ??10 ??11 ??12 ??11 ??10 ??11 | ??87.96±29.56 ??71.58±35.64 ??88.55±32.24 ??98.07±36.83 ??104.30±46.61 ??91.62±43.81 | ??28.02±5.49 ??25.82±7.79 ??23.38±8.23 ??26.78±3.51 ??29.70±13.22 ??26.30±4.92 | ??81.63±39.80 ??57.86±32.72 ??61.02±44.79 ??74.79±26.26 ??73.99±36.04 ??77.19±37.07 | ??3.70±0.58 ??4.50±1.40 ??3.52±1.14 ??3.24±0.90 *??3.18±1.30 ??3.74±1.01 | ?46.30±10.97 ?60.38±9.28 △△??54.15±7.76 ?49.5±6.80 **?48.17±15.68 **?51.75±5.99 * |
Compare with sham operated rats; △ P＜0.05, △ △ P＜0.01; Compare with model group: * P＜0.05, * * P＜0.01;
2.3 influence to MCAO rat blood serum AST, LDH and body weight:
Model group rat blood serum AST and LDH activity obviously increase and the back 24h body weight of performing the operation significantly descends, the ischemia resisting capsule can obviously reduce the release of LDH, and have and reduce the active trend of AST (high dose group is near significant difference), show that to alleviate the brain tissue impairment effect remarkable.The results are shown in Table 6.
Table 6. ischemia resisting capsule is to the influence of MCAO rat blood serum AST, LDH and body weight
| Group | Dosage (/kg) | Number of animals (only) | Body weight (X ± SD, g) | Sero-enzyme (X ± SD, u/L)) | ||||
| Before the administration | Before the operation | Postoperative 6h | Postoperative 24h | ??AST | ??LDH | |||
| Sham-operation model nimodipine Herba Erigerontis tablet ischemia resisting | ??10ml ??10ml ??50mg ??40mg ??140mg ??420mg | ??10 ??11 ??12 ??11 ??10 ??11 | ??258.0±15.5 ??257.3±10.1 ??259.6±14.5 ??259.1±13.0 ??258.0±12.7 ??257.3±10.1 | ??269.5±16.6 ??267.7±9.6 ??265.8±12.9 ??267.7±19.4 ??266.5±16.7 ??266.4±14.5 | ??258.0±15.8 ??252.3±7.5 ??257.1±11.4 ??256.8±15.7 ??253.5±18.1 ??255.9±13.8 | ??255.5±16.6 ??240.0±8.7 △????249.6±10.5 *??247.3±15.4 ??244.0±14.5 ??245.5±11.1 | ??156.0±51.0 ??246.6±121.5 △????198.6±118.2 ??244.3±183.6 ??184.0±111.4 ??165.1±41.92 | ??566.1±191.2 ??907.1±256.7 △△????536.7±262.8 **??719.5±133.4 *??496.2±294.0 **??539.1±269.5 ** |
Compare with sham operated rats: △ P＜0.05, △ △ P＜0.01; Compare with model group: * P＜0.05, * * P＜0.01;
Four, brief summary
Selecting the animal model of and good reproducibility close with human diseases, is the basis of estimating medication effect.Two kinds of animal models close with human diseases are adopted in this research, measure multiple pharmacodynamic index, and overall merit ischemia resisting capsule is to the influence of acute cardiac-cerebral ischemia.The result shows; the ischemia resisting capsule can obviously improve the electrocardiogram variation that coronary artery ligation causes rats with myocardial ischemia; reduce the activity of serum CK-MB and LDH; dwindle myocardial infarct size; anticoagulant; and have the trend that prolongs clotting time and reduce fibrinogen content, point out it that cardiac muscle is lacked and obvious protective effect is arranged.Ischemia resisting not only can reduce MCAO rat cerebral infarction scope, make the behavior disorder degree be improved significantly, the active of LDH obviously reduces in the serum; Simultaneously can also obviously suppress inductive platelet aggregation, and certain anticoagulant trend is arranged, thereby suppress thrombosis by ADP.Result of study shows that the ischemia resisting capsule has remarkable protective effect to cardiac-cerebral ischemia.
The specific embodiment
Embodiment 1:
Raw material: Radix Notoginseng total arasaponins, Semen Ginkgo extrac, Radix Salviae Miltiorrhizae extract are the commercially available prod.
Get Radix Notoginseng total arasaponins 1200 grams, Semen Ginkgo extrac 100 grams, Radix Salviae Miltiorrhizae extract (tanshinone) 700 grams are made capsule after the mixing.
Embodiment 2:
Get Radix Notoginseng total arasaponins 680 grams, Semen Ginkgo extrac 1300 grams, Radix Salviae Miltiorrhizae extract (tanshinone) 20 grams are made capsule after the mixing.
Embodiment 3:
Get Radix Notoginseng total arasaponins 300 grams, Semen Ginkgo extrac 1000 grams, Radix Salviae Miltiorrhizae extract (poly phenolic acid of Radix Salviae Miltiorrhizae) 700 grams are made capsule after the mixing.
Embodiment 4:
Get Radix Notoginseng total arasaponins 1200 grams, Semen Ginkgo extrac 750 grams, Radix Salviae Miltiorrhizae extract (poly phenolic acid of Radix Salviae Miltiorrhizae) 50 grams are made capsule after the mixing.
Claims (4)
1. an anti-cardiac-cerebral ischemia, lipotropic medicine is characterized in that it being the medicament of being made by following materials of weight proportions: Radix Notoginseng total arasaponins 15～60%, Folium Ginkgo extract 15～70%, Radix Salviae Miltiorrhizae extract 0.5～40%.
2. anti-cardiac-cerebral ischemia according to claim 1, lipotropic medicine is characterized in that described Radix Notoginseng total arasaponins contains ginsenoside Rb1, ginsenoside Rg1.
3. anti-cardiac-cerebral ischemia according to claim 1, lipotropic medicine is characterized in that described Folium Ginkgo extract is ginkgetin and Semen Ginkgo lactone.
4. anti-cardiac-cerebral ischemia according to claim 1, lipotropic medicine is characterized in that described Radix Salviae Miltiorrhizae extract is poly phenolic acid of Radix Salviae Miltiorrhizae or tanshinone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510010790 CN1695678A (en) | 2005-04-30 | 2005-04-30 | Medication for anti ischemia on heart and brain, as well as preventing and treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510010790 CN1695678A (en) | 2005-04-30 | 2005-04-30 | Medication for anti ischemia on heart and brain, as well as preventing and treating fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1695678A true CN1695678A (en) | 2005-11-16 |
Family
ID=35348667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510010790 Pending CN1695678A (en) | 2005-04-30 | 2005-04-30 | Medication for anti ischemia on heart and brain, as well as preventing and treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1695678A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850129B (en) * | 2006-03-03 | 2010-05-12 | 广西医科大学 | Medicine preparation for preventing and treating heart brain and kidney blood vessel diseases |
| CN102058665A (en) * | 2011-01-10 | 2011-05-18 | 中国中医科学院广安门医院 | Medicinal composition for treating coronary heart disease and preparation method thereof |
| CN102397310A (en) * | 2011-09-29 | 2012-04-04 | 玉溪市维和维生堂保健食品有限公司 | Pseudo-ginseng triol set and ginkgo biloba leaf extract composition, and preparation and application thereof |
| CN101721493B (en) * | 2009-11-13 | 2012-07-18 | 上海新康制药厂 | Fat-reducing medicine and preparation method and application thereof |
| CN101612296B (en) * | 2009-06-12 | 2013-04-10 | 贵州百灵企业集团制药股份有限公司 | Use of medicaments for treating cardiac-cerebral vascular diseases and post-stroke syndromes in preparation of medicaments for treating fatty liver |
| CN103976356A (en) * | 2014-05-07 | 2014-08-13 | 王浩 | Fat reducing food and making method thereof |
| CN103989723A (en) * | 2014-06-17 | 2014-08-20 | 史克勇 | Drug for treating myocardial ischemia |
| CN104000884A (en) * | 2014-06-17 | 2014-08-27 | 史克勇 | Pharmaceutical composition for relieving myocardial ischemia |
| CN104042735A (en) * | 2014-06-19 | 2014-09-17 | 史克勇 | Medicament for alleviating myocardial ischemia |
| CN106474283A (en) * | 2016-11-16 | 2017-03-08 | 新乡医学院 | A kind of composition of antiatherosclerosis cardiac-cerebral ischemia and application |
-
2005
- 2005-04-30 CN CN 200510010790 patent/CN1695678A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850129B (en) * | 2006-03-03 | 2010-05-12 | 广西医科大学 | Medicine preparation for preventing and treating heart brain and kidney blood vessel diseases |
| CN101612296B (en) * | 2009-06-12 | 2013-04-10 | 贵州百灵企业集团制药股份有限公司 | Use of medicaments for treating cardiac-cerebral vascular diseases and post-stroke syndromes in preparation of medicaments for treating fatty liver |
| CN101721493B (en) * | 2009-11-13 | 2012-07-18 | 上海新康制药厂 | Fat-reducing medicine and preparation method and application thereof |
| CN102058665A (en) * | 2011-01-10 | 2011-05-18 | 中国中医科学院广安门医院 | Medicinal composition for treating coronary heart disease and preparation method thereof |
| CN102397310A (en) * | 2011-09-29 | 2012-04-04 | 玉溪市维和维生堂保健食品有限公司 | Pseudo-ginseng triol set and ginkgo biloba leaf extract composition, and preparation and application thereof |
| CN102397310B (en) * | 2011-09-29 | 2015-08-19 | 玉溪市维和维生堂保健食品有限公司 | Notoginseng triol group and ginkgo leaf extract composition and preparation and purposes |
| CN103976356A (en) * | 2014-05-07 | 2014-08-13 | 王浩 | Fat reducing food and making method thereof |
| CN103989723A (en) * | 2014-06-17 | 2014-08-20 | 史克勇 | Drug for treating myocardial ischemia |
| CN104000884A (en) * | 2014-06-17 | 2014-08-27 | 史克勇 | Pharmaceutical composition for relieving myocardial ischemia |
| CN104042735A (en) * | 2014-06-19 | 2014-09-17 | 史克勇 | Medicament for alleviating myocardial ischemia |
| CN106474283A (en) * | 2016-11-16 | 2017-03-08 | 新乡医学院 | A kind of composition of antiatherosclerosis cardiac-cerebral ischemia and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1695678A (en) | Medication for anti ischemia on heart and brain, as well as preventing and treating fatty liver | |
| CN102908583B (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation method, quality detection method and application of composition | |
| CN100546615C (en) | Be used for the treatment of Chinese medicine composition of cerebrovascular and preparation method thereof | |
| CN1686148A (en) | Use of liposoluble stilbene glycoside kind compound in treating ischemic heart brain blood vessel disease and its preparation | |
| CN102441156B (en) | Traditional Tibetan medicinal composition and preparation method thereof | |
| CN100339111C (en) | Medicine for treating coronary heart disease and its prepn | |
| CN103006769B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN107875144B (en) | A kind of combination of oral medication for treating depression | |
| CN101697989B (en) | Application of notoginseng and extract thereof in preparing medicaments for treating and/or preventing coronary artherosclerosis | |
| CN101700265A (en) | Application of pseudo-ginseng and extract thereof in preparing medicament for curing and/or preventing diabetic microangiopathies | |
| CN102961517A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN101700264B (en) | Application of pseudo-ginseng and extract thereof in preparing medicament for curing and/or preventing diabetic neuropathies | |
| CN102068520A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1254252C (en) | Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method | |
| CN1718191A (en) | Total secondary ginseng glucoside oral disintegration tablets prepn. method and application thereof | |
| CN1220504C (en) | Medicine for treating coronary disease and preparing method thereof | |
| CN103055011A (en) | G6 lectin extracted from traditional Chinese medicines and applications thereof in detoxification, pressure stabilization, blood vessel softening and complication resistance | |
| CN1316992C (en) | Medicine for treating heart brain embulus disease and its preparation method | |
| CN102948734A (en) | Compound propolis soft-capsule for auxiliary reduction of blood sugar, and its preparation method | |
| CN102772665B (en) | Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof | |
| CN102836320B (en) | Chinese medicinal pill for treating tachyarrhythmia | |
| CN1682972A (en) | Chinese medicine composition for treating cardiovascular disease and its preparing method | |
| CN1857293A (en) | Medicine composition containing wild astragaloside and paeoniforin | |
| CN100531740C (en) | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels | |
| CN1079658A (en) | A kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |